Deleobuvir (original) (raw)

Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C. It was being developed by Boehringer Ingelheim. It is a non-nucleoside hepatitis C virus NS5B polymerase inhibitor. Deleobuvir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including faldaprevir. In December 2013, Boehringer Ingelheim announced that the development of deleobuvir would not be continued since recent findings from phase III trials did not suggest sufficient efficacy.